vTv Therapeutics (NASDAQ:VTVT) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Other equities analysts also recently issued reports about the company. HC Wainwright restated a buy rating on shares of vTv Therapeutics in a research report on Wednesday, March 18th. Northland Securities started coverage on vTv Therapeutics in a research note on Monday, June 15th. They set a buy rating and a $8.00 target price for the company. Finally, ValuEngine cut vTv Therapeutics from a buy rating to a hold rating in a research note on Monday, June 8th.

Shares of VTVT opened at $2.23 on Friday. vTv Therapeutics has a 1 year low of $1.23 and a 1 year high of $4.23. The company has a market capitalization of $153.17 million, a price-to-earnings ratio of -4.74 and a beta of -1.84. The business has a 50-day moving average of $2.75 and a 200-day moving average of $2.35.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). The firm had revenue of $0.01 million during the quarter. On average, research analysts predict that vTv Therapeutics will post -0.43 EPS for the current fiscal year.

In other news, major shareholder Ronald O. Perelman acquired 625,000 shares of vTv Therapeutics stock in a transaction on Tuesday, May 12th. The stock was purchased at an average price of $1.60 per share, with a total value of $1,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hersh Kozlov acquired 10,000 shares of vTv Therapeutics stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $3.00 per share, with a total value of $30,000.00. Following the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $45,000. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company’s stock.

A number of institutional investors have recently made changes to their positions in VTVT. Frazier Management LLC acquired a new stake in vTv Therapeutics in the first quarter valued at approximately $2,028,000. Two Sigma Investments LP grew its stake in vTv Therapeutics by 206.1% in the first quarter. Two Sigma Investments LP now owns 270,295 shares of the biotechnology company’s stock valued at $516,000 after acquiring an additional 181,995 shares during the period. Bank of America Corp DE grew its stake in vTv Therapeutics by 15,237.9% in the fourth quarter. Bank of America Corp DE now owns 129,145 shares of the biotechnology company’s stock valued at $220,000 after acquiring an additional 128,303 shares during the period. Barclays PLC purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at approximately $217,000. Finally, Renaissance Technologies LLC purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at approximately $66,000. 8.23% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Further Reading: What is a Call Option?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.